Nicholas Borys Net Worth

The estimated Net Worth of Nicholas Borys is at least $895 Thousand dollars as of 12 December 2011. Nicholas Borys owns over 5,000 units of Imunon Inc stock worth over $69,947 and over the last 16 years he sold CLSN stock worth over $0. In addition, he makes $824,966 as Senior Vice President and Chief Medical Officer at Imunon Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Nicholas Borys CLSN stock SEC Form 4 insiders trading

Nicholas has made over 3 trades of the Imunon Inc stock since 2008, according to the Form 4 filled with the SEC. Most recently he bought 5,000 units of CLSN stock worth $10,000 on 12 December 2011.

The largest trade he's ever made was buying 6,000 units of Imunon Inc stock on 19 November 2008 worth over $15,000. On average, Nicholas trades about 602 units every 53 days since 2008. As of 12 December 2011 he still owns at least 35,687 units of Imunon Inc stock.

You can see the complete history of Nicholas Borys stock trades at the bottom of the page.

Nicholas Borys biography

Dr. Nicholas Borys, M.D., is Senior Vice President and Chief Medical Officer of Celsion Corporation., since October 1, 2007. Dr. Borys joined Celsion on October 1, 2007 as Vice President and Chief Medical Officer of the Company and was promoted to Senior Vice President in June 2014. In this position, Dr. Borys manages the clinical development and regulatory programs for Celsion. Dr. Borys has over 20 years of experience in all phases of pharmaceutical development with a focus on oncology. Immediately prior to joining Celsion, Dr. Borys served as Chief Medical Officer of Molecular Insight Pharmaceuticals, Inc., a molecular imaging and nuclear oncology pharmaceutical company, from 2004 until 2007. From 2002 until 2004 he served as the Vice President and Chief Medical Officer of Taiho Pharma USA, a Japanese start-up oncology therapeutics company. Prior to that he held increasingly senior positions at Cytogen Corporation, Anthra Pharmaceuticals, Inc., Amersham Healthcare, Inc. and Hoffmann La-Roche Inc. Dr. Borys obtained his premedical degree from Rutgers University and holds an M.D. degree from American University of the Caribbean.

What is the salary of Nicholas Borys?

As the Senior Vice President and Chief Medical Officer of Imunon Inc, the total compensation of Nicholas Borys at Imunon Inc is $824,966. There are 2 executives at Imunon Inc getting paid more, with Michael Tardugno having the highest compensation of $1,694,790.

How old is Nicholas Borys?

Nicholas Borys is 55, he's been the Senior Vice President and Chief Medical Officer of Imunon Inc since 2014. There are 12 older and no younger executives at Imunon Inc. The oldest executive at Imunon Inc is Michael H. Tardugno, 70, who is the Exec. Chairman, Pres & CEO.

What's Nicholas Borys's mailing address?

Nicholas's mailing address filed with the SEC is 10220-L OLD COLUMBIA ROAD, , COLUMBIA, MD, 21046.

Insiders trading at Imunon Inc

Over the last 17 years, insiders at Imunon Inc have traded over $895,739 worth of Imunon Inc stock and bought 973,579 units worth $2,229,348 . The most active insiders traders include Gary W Pace, Max Link, and Sean F. Moran. On average, Imunon Inc executives and independent directors trade stock every 38 days with the average trade being worth of $22,407. The most recent stock trade was executed by Michael H Tardugno on 12 April 2022, trading 4,000 units of CLSN stock currently worth $14,120.

What does Imunon Inc do?

Celsion is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative cancer treatments, including immunotherapies and DNA-based therapies; and a platform for the development of nucleic acid vaccines currently focused on SARS-CoV2. The company's product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer. ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, is under investigator-sponsored development for several cancer indications. Celsion also has two feasibility stage platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies. Both are novel synthetic, non-viral vectors with demonstrated capability in nucleic acid cellular transfection.

Complete history of Nicholas Borys stock trades at Imunon Inc

Imunon Inc executives and stock owners

Imunon Inc executives and other stock owners filed with the SEC include:

• Michael Tardugno,
  Executive Chairman of the Board, President, Chief Executive Officer
• Michael H. Tardugno,
  Exec. Chairman, Pres & CEO
• Nicholas Borys,
  Senior Vice President and Chief Medical Officer
• Jeffrey Church,
  Chief Financial Officer, Senior Vice President, Corporate Secretary, IR Contact Officer
• Dr. Nicholas Borys,
  Exec. VP & Chief Medical Officer
• Jeffrey W. Church CPA, CPA,
  CFO, Exec. VP & Corp. Sec.
• Dr. Khursheed Anwer M.B.A., Ph.D.,
  Exec. VP & Chief Scientific Officer
• Khursheed Anwer,
  Executive Vice President, Chief Scientific Officer - Nucleic Acid Therapy
• Dr. Khursheed Anwer,
  Exec. VP & Chief Scientific Officer
• Andreas Voss,
  Independent Director
• Alberto Martinez,
  Independent Director
• Robert Hooper,
  Independent Director
• Frederick Fritz,
  Independent Director
• Pok Yu Chow,
  Independent Director
• Donald Braun,
  Independent Director
• Marianne M. Lambertson,
  VP of Communications & Investor Relations
• Timothy J. Tumminello,
  Chief Accounting Officer & Controller
• Sean F. Moran,
  Chief Financial Officer
• Gary W Pace,
  Director
• Stacy Lindborg,
  Director
• Christine A Pellizzari,
  Director
• Timothy J Tumminello,
  Controller
• Inc. Fka Egen, Inc. Egwu,,
  10% owner
• Max Link,
  Director
• Gregory L Weaver,
  Director
• Goff Corinne Le,
  President and CEO
• Constantine John Kardaras,
  Chief Accounting Officer